CSP
REGN icon

Cary Street Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Cary Street Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Hold
162
– – ﹤0.01% 1000
2026
Q1 		$125K Buy
162
+14
+9% +$10.7K ﹤0.01% 886
2025
Q4 		$114K Buy
148
+2
+1% +$1.36K ﹤0.01% 895
2025
Q3 		$81.9K Buy
146
+7
+5% +$3.96K ﹤0.01% 872
2025
Q2 		$72.8K Sell
139
-116
-45% -$64.7K ﹤0.01% 852
2025
Q1 		$162K Sell
255
-959
-79% -$660K 0.01% 782
2024
Q4 		$865K Buy
+1,214
New +$1.02M 0.03% 407

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cary Street Partners's REGN Position: Q2 2026 in Review

Cary Street Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 162 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

Cary Street Partners first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $865K in Q4 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cary Street Partners held 162 shares of Regeneron Pharmaceuticals worth $101K as of Q2 2026.
  • Cary Street Partners left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Cary Street Partners's portfolio in Q2 2026, its #1000 holding.
  • Cary Street Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Cary Street Partners's Regeneron Pharmaceuticals position peaked at $865K in Q4 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.